The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global PD-1&PD-L1 Immunotherapy Market Research Report 2025
Synopsis
A protein found on T cells (a type of immune cell) that helps keep the body's immune responses in check. When PD-1 is bound to another protein called PD-L1, it helps keep T cells from killing other cells, including cancer cells. Some anticancer drugs, called immune checkpoint inhibitors, are used to block PD-1.
The global PD-1&PD-L1 Immunotherapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for PD-1&PD-L1 Immunotherapy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for PD-1&PD-L1 Immunotherapy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of PD-1&PD-L1 Immunotherapy include AstraZeneca Plc, BeiGene, Ltd., Bristol-Myers Squibb Company, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Eli Lilly & Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Innovent Biologics, Inc. and Jiangsu HengRui Medicine Co., Ltd., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for PD-1&PD-L1 Immunotherapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-1&PD-L1 Immunotherapy.
Report Scope
The PD-1&PD-L1 Immunotherapy market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global PD-1&PD-L1 Immunotherapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PD-1&PD-L1 Immunotherapy manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca Plc
BeiGene, Ltd.
Bristol-Myers Squibb Company
Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
Eli Lilly & Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Innovent Biologics, Inc.
Jiangsu HengRui Medicine Co., Ltd.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Sanofi S.A.
Segment by Type
PD-1 Inhibitors
PD-L1 Inhibitors
Segment by Application
Non-Small Cell Lung Cancer
Esophageal Cancer
Urothelial Carcinoma
Hepatocellular Carcinoma
Small Cell Lung Cancer
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of PD-1&PD-L1 Immunotherapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of PD-1&PD-L1 Immunotherapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
A protein found on T cells (a type of immune cell) that helps keep the body's immune responses in check. When PD-1 is bound to another protein called PD-L1, it helps keep T cells from killing other cells, including cancer cells. Some anticancer drugs, called immune checkpoint inhibitors, are used to block PD-1.
The global PD-1&PD-L1 Immunotherapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for PD-1&PD-L1 Immunotherapy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for PD-1&PD-L1 Immunotherapy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of PD-1&PD-L1 Immunotherapy include AstraZeneca Plc, BeiGene, Ltd., Bristol-Myers Squibb Company, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Eli Lilly & Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Innovent Biologics, Inc. and Jiangsu HengRui Medicine Co., Ltd., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for PD-1&PD-L1 Immunotherapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-1&PD-L1 Immunotherapy.
Report Scope
The PD-1&PD-L1 Immunotherapy market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global PD-1&PD-L1 Immunotherapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PD-1&PD-L1 Immunotherapy manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca Plc
BeiGene, Ltd.
Bristol-Myers Squibb Company
Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
Eli Lilly & Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Innovent Biologics, Inc.
Jiangsu HengRui Medicine Co., Ltd.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Sanofi S.A.
Segment by Type
PD-1 Inhibitors
PD-L1 Inhibitors
Segment by Application
Non-Small Cell Lung Cancer
Esophageal Cancer
Urothelial Carcinoma
Hepatocellular Carcinoma
Small Cell Lung Cancer
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of PD-1&PD-L1 Immunotherapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of PD-1&PD-L1 Immunotherapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 PD-1&PD-L1 Immunotherapy Market Overview
1.1 Product Overview and Scope of PD-1&PD-L1 Immunotherapy
1.2 PD-1&PD-L1 Immunotherapy Segment by Type
1.2.1 Global PD-1&PD-L1 Immunotherapy Market Value Comparison by Type (2024-2030)
1.2.2 PD-1 Inhibitors
1.2.3 PD-L1 Inhibitors
1.3 PD-1&PD-L1 Immunotherapy Segment by Application
1.3.1 Global PD-1&PD-L1 Immunotherapy Market Value by Application: (2024-2030)
1.3.2 Non-Small Cell Lung Cancer
1.3.3 Esophageal Cancer
1.3.4 Urothelial Carcinoma
1.3.5 Hepatocellular Carcinoma
1.3.6 Small Cell Lung Cancer
1.3.7 Others
1.4 Global PD-1&PD-L1 Immunotherapy Market Size Estimates and Forecasts
1.4.1 Global PD-1&PD-L1 Immunotherapy Revenue 2019-2030
1.4.2 Global PD-1&PD-L1 Immunotherapy Sales 2019-2030
1.4.3 Global PD-1&PD-L1 Immunotherapy Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 PD-1&PD-L1 Immunotherapy Market Competition by Manufacturers
2.1 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Manufacturers (2019-2024)
2.2 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Manufacturers (2019-2024)
2.3 Global PD-1&PD-L1 Immunotherapy Average Price by Manufacturers (2019-2024)
2.4 Global PD-1&PD-L1 Immunotherapy Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of PD-1&PD-L1 Immunotherapy, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of PD-1&PD-L1 Immunotherapy, Product Type & Application
2.7 PD-1&PD-L1 Immunotherapy Market Competitive Situation and Trends
2.7.1 PD-1&PD-L1 Immunotherapy Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest PD-1&PD-L1 Immunotherapy Players Market Share by Revenue
2.7.3 Global PD-1&PD-L1 Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 PD-1&PD-L1 Immunotherapy Retrospective Market Scenario by Region
3.1 Global PD-1&PD-L1 Immunotherapy Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global PD-1&PD-L1 Immunotherapy Global PD-1&PD-L1 Immunotherapy Sales by Region: 2019-2030
3.2.1 Global PD-1&PD-L1 Immunotherapy Sales by Region: 2019-2024
3.2.2 Global PD-1&PD-L1 Immunotherapy Sales by Region: 2025-2030
3.3 Global PD-1&PD-L1 Immunotherapy Global PD-1&PD-L1 Immunotherapy Revenue by Region: 2019-2030
3.3.1 Global PD-1&PD-L1 Immunotherapy Revenue by Region: 2019-2024
3.3.2 Global PD-1&PD-L1 Immunotherapy Revenue by Region: 2025-2030
3.4 North America PD-1&PD-L1 Immunotherapy Market Facts & Figures by Country
3.4.1 North America PD-1&PD-L1 Immunotherapy Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America PD-1&PD-L1 Immunotherapy Sales by Country (2019-2030)
3.4.3 North America PD-1&PD-L1 Immunotherapy Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe PD-1&PD-L1 Immunotherapy Market Facts & Figures by Country
3.5.1 Europe PD-1&PD-L1 Immunotherapy Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe PD-1&PD-L1 Immunotherapy Sales by Country (2019-2030)
3.5.3 Europe PD-1&PD-L1 Immunotherapy Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific PD-1&PD-L1 Immunotherapy Market Facts & Figures by Country
3.6.1 Asia Pacific PD-1&PD-L1 Immunotherapy Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific PD-1&PD-L1 Immunotherapy Sales by Country (2019-2030)
3.6.3 Asia Pacific PD-1&PD-L1 Immunotherapy Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America PD-1&PD-L1 Immunotherapy Market Facts & Figures by Country
3.7.1 Latin America PD-1&PD-L1 Immunotherapy Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America PD-1&PD-L1 Immunotherapy Sales by Country (2019-2030)
3.7.3 Latin America PD-1&PD-L1 Immunotherapy Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa PD-1&PD-L1 Immunotherapy Market Facts & Figures by Country
3.8.1 Middle East and Africa PD-1&PD-L1 Immunotherapy Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa PD-1&PD-L1 Immunotherapy Sales by Country (2019-2030)
3.8.3 Middle East and Africa PD-1&PD-L1 Immunotherapy Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global PD-1&PD-L1 Immunotherapy Sales by Type (2019-2030)
4.1.1 Global PD-1&PD-L1 Immunotherapy Sales by Type (2019-2024)
4.1.2 Global PD-1&PD-L1 Immunotherapy Sales by Type (2025-2030)
4.1.3 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2019-2030)
4.2 Global PD-1&PD-L1 Immunotherapy Revenue by Type (2019-2030)
4.2.1 Global PD-1&PD-L1 Immunotherapy Revenue by Type (2019-2024)
4.2.2 Global PD-1&PD-L1 Immunotherapy Revenue by Type (2025-2030)
4.2.3 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2019-2030)
4.3 Global PD-1&PD-L1 Immunotherapy Price by Type (2019-2030)
5 Segment by Application
5.1 Global PD-1&PD-L1 Immunotherapy Sales by Application (2019-2030)
5.1.1 Global PD-1&PD-L1 Immunotherapy Sales by Application (2019-2024)
5.1.2 Global PD-1&PD-L1 Immunotherapy Sales by Application (2025-2030)
5.1.3 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2019-2030)
5.2 Global PD-1&PD-L1 Immunotherapy Revenue by Application (2019-2030)
5.2.1 Global PD-1&PD-L1 Immunotherapy Revenue by Application (2019-2024)
5.2.2 Global PD-1&PD-L1 Immunotherapy Revenue by Application (2025-2030)
5.2.3 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2019-2030)
5.3 Global PD-1&PD-L1 Immunotherapy Price by Application (2019-2030)
6 Key Companies Profiled
6.1 AstraZeneca Plc
6.1.1 AstraZeneca Plc Corporation Information
6.1.2 AstraZeneca Plc Description and Business Overview
6.1.3 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2019-2024)
6.1.4 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Product Portfolio
6.1.5 AstraZeneca Plc Recent Developments/Updates
6.2 BeiGene, Ltd.
6.2.1 BeiGene, Ltd. Corporation Information
6.2.2 BeiGene, Ltd. Description and Business Overview
6.2.3 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2019-2024)
6.2.4 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio
6.2.5 BeiGene, Ltd. Recent Developments/Updates
6.3 Bristol-Myers Squibb Company
6.3.1 Bristol-Myers Squibb Company Corporation Information
6.3.2 Bristol-Myers Squibb Company Description and Business Overview
6.3.3 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Product Portfolio
6.3.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
6.4.1 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Corporation Information
6.4.2 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Description and Business Overview
6.4.3 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio
6.4.5 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Recent Developments/Updates
6.5 Eli Lilly & Company
6.5.1 Eli Lilly & Company Corporation Information
6.5.2 Eli Lilly & Company Description and Business Overview
6.5.3 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Product Portfolio
6.5.5 Eli Lilly & Company Recent Developments/Updates
6.6 F. Hoffmann-La Roche Ltd
6.6.1 F. Hoffmann-La Roche Ltd Corporation Information
6.6.2 F. Hoffmann-La Roche Ltd Description and Business Overview
6.6.3 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2019-2024)
6.6.4 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Product Portfolio
6.6.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
6.7 GlaxoSmithKline plc
6.6.1 GlaxoSmithKline plc Corporation Information
6.6.2 GlaxoSmithKline plc Description and Business Overview
6.6.3 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2019-2024)
6.4.4 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Product Portfolio
6.7.5 GlaxoSmithKline plc Recent Developments/Updates
6.8 Innovent Biologics, Inc.
6.8.1 Innovent Biologics, Inc. Corporation Information
6.8.2 Innovent Biologics, Inc. Description and Business Overview
6.8.3 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
6.8.5 Innovent Biologics, Inc. Recent Developments/Updates
6.9 Jiangsu HengRui Medicine Co., Ltd.
6.9.1 Jiangsu HengRui Medicine Co., Ltd. Corporation Information
6.9.2 Jiangsu HengRui Medicine Co., Ltd. Description and Business Overview
6.9.3 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio
6.9.5 Jiangsu HengRui Medicine Co., Ltd. Recent Developments/Updates
6.10 Merck & Co., Inc.
6.10.1 Merck & Co., Inc. Corporation Information
6.10.2 Merck & Co., Inc. Description and Business Overview
6.10.3 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
6.10.5 Merck & Co., Inc. Recent Developments/Updates
6.11 Novartis AG
6.11.1 Novartis AG Corporation Information
6.11.2 Novartis AG PD-1&PD-L1 Immunotherapy Description and Business Overview
6.11.3 Novartis AG PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Novartis AG PD-1&PD-L1 Immunotherapy Product Portfolio
6.11.5 Novartis AG Recent Developments/Updates
6.12 Pfizer Inc.
6.12.1 Pfizer Inc. Corporation Information
6.12.2 Pfizer Inc. PD-1&PD-L1 Immunotherapy Description and Business Overview
6.12.3 Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Pfizer Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
6.12.5 Pfizer Inc. Recent Developments/Updates
6.13 Regeneron Pharmaceuticals Inc.
6.13.1 Regeneron Pharmaceuticals Inc. Corporation Information
6.13.2 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Description and Business Overview
6.13.3 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
6.13.5 Regeneron Pharmaceuticals Inc. Recent Developments/Updates
6.14 Sanofi S.A.
6.14.1 Sanofi S.A. Corporation Information
6.14.2 Sanofi S.A. PD-1&PD-L1 Immunotherapy Description and Business Overview
6.14.3 Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Sanofi S.A. PD-1&PD-L1 Immunotherapy Product Portfolio
6.14.5 Sanofi S.A. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 PD-1&PD-L1 Immunotherapy Industry Chain Analysis
7.2 PD-1&PD-L1 Immunotherapy Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 PD-1&PD-L1 Immunotherapy Production Mode & Process
7.4 PD-1&PD-L1 Immunotherapy Sales and Marketing
7.4.1 PD-1&PD-L1 Immunotherapy Sales Channels
7.4.2 PD-1&PD-L1 Immunotherapy Distributors
7.5 PD-1&PD-L1 Immunotherapy Customers
8 PD-1&PD-L1 Immunotherapy Market Dynamics
8.1 PD-1&PD-L1 Immunotherapy Industry Trends
8.2 PD-1&PD-L1 Immunotherapy Market Drivers
8.3 PD-1&PD-L1 Immunotherapy Market Challenges
8.4 PD-1&PD-L1 Immunotherapy Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
